FRI0181 Sirukumab, a human anti-IL-6 monoclonal antibody, improves physical function in patients with active ra despite methotrexate therapy: Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study

THU0100 Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2065 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 188.1-188 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

J.S. Smolen ◽

M.E. Weinblatt

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Methotrexate Therapy ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Dose Ranging

OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.1708 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 61.1-61 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

M.E. Weinblatt ◽

J.S. Smolen

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Methotrexate Therapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733519001.793576228 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Ankylosing Spondylitis ◽

Dose Finding ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3523879 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of maintenance therapy with anti-TA-MUC1 monoclonal antibody PankoMab after chemotherapy in patients with recurrent epithelial ovarian carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps5622 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS5622-TPS5622

Author(s):

Jonathan A. Ledermann ◽

Ingo von Broen ◽

Frank Zimmermann ◽

Johannes Nippgen ◽

Steffen Goletz

Keyword(s):

Monoclonal Antibody ◽

Maintenance Therapy ◽

Ovarian Carcinoma ◽

Epithelial Ovarian Carcinoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Randomized Phase 2

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

The Lancet ◽

10.1016/s0140-6736(12)61771-1 ◽

2012 ◽

Vol 380 (9858) ◽

pp. 1995-2006 ◽

Cited By ~ 256

Author(s):

Michael J Koren ◽

Rob Scott ◽

Jae B Kim ◽

Beat Knusel ◽

Thomas Liu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase 2 ◽

Proprotein Convertase ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double‐blind, Placebo‐controlled Phase 2 study

Arthritis & Rheumatology ◽

10.1002/art.41555 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733519001.793552052 ◽

2018 ◽

Author(s):

Hill Gaston

Keyword(s):

Ankylosing Spondylitis ◽

Dose Finding ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and Safety of Mirogabalin (DS-5565) for the Treatment of Diabetic Peripheral Neuropathic Pain: A Randomized, Double-Blind, Placebo- and Active Comparator–Controlled, Adaptive Proof-of-Concept Phase 2 Study

Diabetes Care ◽

10.2337/dc14-1044 ◽

2014 ◽

Vol 37 (12) ◽

pp. 3253-3261 ◽

Cited By ~ 43

Author(s):

Aaron Vinik ◽

Julio Rosenstock ◽

Uma Sharma ◽

Karen Feins ◽

Ching Hsu ◽

...

Keyword(s):

Neuropathic Pain ◽

Phase 2 ◽

Proof Of Concept ◽

Efficacy And Safety ◽

Double Blind ◽

Peripheral Neuropathic Pain ◽

Double Blind Placebo ◽

Active Comparator ◽

Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(18)30105-0 ◽

2018 ◽

Vol 6 (8) ◽

pp. 627-636 ◽

Cited By ~ 13

Author(s):

Dalong Zhu ◽

Shenglian Gan ◽

Yu Liu ◽

Jianhua Ma ◽

Xiaolin Dong ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chinese Patients ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Dose Ranging